Cat. No. |
Product Name |
Information |
PC-42040 |
Bay 41-4109
HBV capsid inhibitor
|
Bay 41-4109 is a potent, non-nucleosidic inhibitor of HBV nucleocapsid maturation with IC50 of 0.05 uM. |
PC-22187 |
GS-6671
HBsAg inhibitor
|
GS-6671 is a potent, orally bioavailable inhibitor of HBV surface antigen (HBsAg) with EC50 of 5.8 nM in HepG2-NTCP assays, via inhibition of the human poly(A) polymerases PAPD5/7, promoting destabilization and degradation of HBV mRNA. |
PC-22186 |
GS-8873
HBsAg inhibitor
|
GS-8873 is a potent, orally bioavailable inhibitor of HBV surface antigen (HBsAg) with EC50 of 4 nM in HepG2-NTCP assays, via inhibition of the human poly(A) polymerases PAPD5/7, promoting destabilization and degradation of HBV mRNA. |
PC-21756 |
SAG-524
HBV inhibitor
|
SAG-524 (SAG524) is a potent and orally bioavailable small molecule inhibitor of HBV replication, reduces HBsAg and HBV-DNA (IC50 = 0.92 nM and 1.4 nM) by destabilizing HBV-RNA. |
PC-21261 |
Alisporivir
Cyclophilin inhibitor
|
Alisporivir (Debio 025, DEBIO-025) is a non-immunosuppressive cyclophilin inhibitor derived from cyclosporin A (CsA) with IC50 of 30 nM (CypD PPIase activity ), inhibits HCV replication in vitro more potently than CsA. |
PC-20678 |
AB-836
HBV capsid inhibitor
|
AB-836 is a next generation oral hepatitis B virus (HBV) capsid inhibitor that interacts with HBV core protein and demonstrates robust antiviral activity. |
PC-20059 |
Neracorvir
HBV inhibitor
|
Neracorvir is a potent anti-HBV agent, targets HBV surface antigen. |
PC-49649 |
E-CFCP
HBV inhibitor
|
E-CFCP is a novel long-acting nucleotide reverse transcriptase inhibitor (NRTI) against HBV, shows potent activity against HBV WTD1 and HBV WTC2 with IC50 of 1.8 and 0.7 nM, respectively. |
PC-49567 |
Vebicorvir
HBV core inhibitor
|
Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor, exhibits selective inhibition of HBV DNA replication with EC50 from 173 nM to 307 nM. |
PC-49553 |
Nitazoxanide
HBx-DDB1 inhibitor
|
Nitazoxanide (NTX) is a thiazolide anti-infective agent that efficiently inhibits the HBV regulatory protein X (HBx)-DDB1 protein interaction, exhibits potent inhibition of both HBV and HCV replication. |
PC-47007 |
DF-006
ALPK1 agonist
|
DF-006 is a small molecule, orally active Alpha-kinase 1 (ALPK1) agonist, activates ALPK1 and stimulates host innate immunity locally in liver, DF-006 enacts potent anti-HBV responses in mouse models of HBV and in primary human hepatocytes. |
PC-38561 |
ATI-2173
HBV inhibitor
|
ATI-2173 is a novel liver-targeted prodrug of clevudine, ATI-2173 is a selective inhibitor of HBV with EC50 of 1.31 nM in primary human hepatocytes with minimal to no toxicity. |